Navigation Links
Novel toxin receptor discovered for ulcer-causing stomach pathogen
Date:5/23/2008

Helicobacter pylori is one tough bug. It can survive in the human stomach, a zone with a pH somewhere between that of lemon juice and battery acid. Now researchers have discovered how an H. pylori toxin gets into cells, a feat that helps the bacterium live in one of the most inhospitable environments in the body.

Their findings appear this week in PLoS Pathogens, a journal of the Public Library of Science.

About half of the worlds population is infected with H. pylori, although most of them dont know it (most infected people have no obvious symptoms). For a percentage of the infected, however, the bacterium packs a nasty punch. H. pylori is responsible for most human cases of gastric and duodenal ulcers, and long-term infection is a significant risk factor for stomach cancer, the second leading cause of cancer death worldwide.

Researchers have tried for years to understand how the bacterium survives in the human stomach, said Steven Blanke, a University of Illinois professor in the department of microbiology and Institute for Genomic Biology and principal investigator on the study.

Paradoxically, although H. pylori is a common resident of the human stomach, the bug is not well adapted by itself to acid, he said. But this pathogen has several clever mechanisms for carving out a niche for itself in the stomach lining.

A protein produced by H. pylori, called vacuolating toxin A (VacA), is an important weapon in its arsenal.

This toxin gets into stomach epithelial cells and immune cells and changes their properties in such a way as to allow H. pylori to first gain a foothold in the stomach, and then survive over the long-term, which may be the entire lifetime of an individual, Blanke said.

H. pylori releases the VacA toxin in order to modify its environment, he said.

How the toxin crossed the membrane to get into these cells was a mystery, however.

Cell membranes are composed primarily of lipids and proteins and are designed to keep things out. Some molecules can penetrate them, but most can do so only after binding to a specific membrane component, called a receptor. Receptors sometimes act as keys that open channels through a membrane, or they function as signaling molecules, communicating to other components in the cell.

Blankes team knew that VacA was latching on to something on the cell surface that was helping it across the membrane.

Other studies had shown that VacA bound to lipids within artificially created membranes, so graduate students Vijay Gupta and Hetal Patel screened a number of lipids for VacA binding and soon found one to which the toxin readily attached. This lipid, called sphingomyelin, is an important and abundant component of the membrane of some animal cells. (Foods such as milk, meat, fish and eggs are dietary sources of sphingomyelin.)

To be considered a receptor, a molecule must meet two criteria, Blanke said. It must bind the agent of interest (in this case VacA) to the cell surface, and it must confer sensitivity to that agent. In other words, a receptor to VacA must be essential to the process by which VacA gets into a cell. If you removed the receptor, or blocked it, the toxin would lose its ability to bind or function. Prior to this study, no molecules on the membrane of human cells had been found that satisfied both criteria as a receptor.

Upon entering cells, VacA spurs the formation of giant vacuoles. These oversized membrane-bound compartments are easy to spot under a microscope and provide a useful indicator of VacA activity in the cell.

To test whether sphingomyelin was a receptor for VacA, Gupta treated cultured human cells with an enzyme that depleted the membranes of sphingomyelin. In the sphingomyelin-depleted cells, the toxin lost its ability to cross into the cells and the giant vacuoles disappeared. When he restored sphingomyelin to the same cell membranes (again, in the presence of VacA), the vacuoles returned.

This is the first example of a bacterial virulence factor that uses sphingomyelin as a receptor, Blanke said. Only sphingomyelin confers sensitivity to the toxin in these cells, whereas other common membrane lipids do not.

Sphingomyelin recently was discovered to have the ability to cluster into specialized membrane islands, or rafts, that look like raised platforms on the cell surface.

Blankes team found that VacA preferentially binds to and enters the cell by means of these sphingomyelin rafts.

Our model is that these platforms serve as the entry portals for the toxin into the cell, Blanke said. We think that sphingomyelin is important because it seems to cluster the toxin in these portals of entry. This seems to be absolutely essential for toxin activity.

Finding the mechanism by which the toxin gets into cells is of great interest to those hoping to treat H. pylori infection, Blanke said.

Identifying toxin receptors is important because they are outstanding targets for new drugs to block the action of toxins on human cells, he said.

Also, because some bacterial toxins are so adept at breeching the membrane barrier to enter human cells, this work may also point the way to new strategies for sending protein-based pharmaceuticals into the cell, he said.


'/>"/>

Contact: Diana Yates
diya@illinois.edu
217-333-5802
University of Illinois at Urbana-Champaign
Source:Eurekalert  

Related medicine news :

1. Novel enzyme inhibitor paves way for new cancer drug
2. Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
3. Novel mechanisms controlling insulin release and fat deposition discovered
4. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
5. Discovery of a novel mechanism for the development of colon cancer
6. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
7. Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
8. Scientists identify novel way to prevent cardiac fibrosis
9. Registry unveils real-world data on novel excel stent
10. Researchers sharpen search for new marine medicines with novel techniques
11. Increased hepcidin expression: A novel oncogenic signalling mechanism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel toxin receptor discovered for ulcer-causing stomach pathogen
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology: